UNITY Biotechnology's Wet AMD Candidate Flunks On Non-Inferiority Threshold Compared To Regeneron's Drug

By: via Benzinga
UNITY Biotechnology Inc(NASDAQ: UBX) announced results from Part A of the Phase 2 ENVISION study of UBX1325 in patients with ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.